The National Comprehensive Cancer Network (NCCN) guidelines confirmed that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) could be used as the standard first-line treatment for EGFR mutation-positive NSCLC patients [7], which represent more than 50% of NSCLC patients in the Asia–Pacific region [8]. Here, EGFR is linked to non-small cell lung carcinoma.